



US010519252B2

(12) **United States Patent**  
**Geisser et al.**

(10) **Patent No.:** **US 10,519,252 B2**  
(45) **Date of Patent:** **\*Dec. 31, 2019**

(54) **AQUEOUS IRON CARBOHYDRATE COMPLEXES, THEIR PRODUCTION AND MEDICAMENTS CONTAINING THEM**

(71) Applicant: **VIFOR (INTERNATIONAL) AG.**, St. Gallen (CH)

(72) Inventors: **Peter Geisser**, St. Gallen (CH); **Erik Philipp**, Arbon (CH); **Walter Richle**, Gossau (CH)

(73) Assignee: **VIFOR (INTERNATIONAL) AG.**, St. Gallen (CH)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/835,400**

(22) Filed: **Mar. 15, 2013**

(65) **Prior Publication Data**

US 2013/0203698 A1 Aug. 8, 2013

**Related U.S. Application Data**

(60) Continuation of application No. 13/556,733, filed on Jul. 24, 2012, now Pat. No. 9,376,505, which is a continuation of application No. 12/581,212, filed on Oct. 19, 2009, now abandoned, which is a division of application No. 10/531,895, filed as application No. PCT/EP03/11596 on Oct. 20, 2003, now Pat. No. 7,612,109.

(30) **Foreign Application Priority Data**

Oct. 23, 2002 (DE) ..... 102 49 552

(51) **Int. Cl.**

**C08B 30/18** (2006.01)  
**A61P 7/06** (2006.01)  
**A61K 31/295** (2006.01)  
**A61K 31/718** (2006.01)  
**A61K 33/26** (2006.01)  
**A61K 47/61** (2017.01)  
**A61K 45/06** (2006.01)  
**C08B 31/18** (2006.01)  
**C08B 37/00** (2006.01)

(52) **U.S. Cl.**

CPC ..... **C08B 30/18** (2013.01); **A61K 31/295** (2013.01); **A61K 31/718** (2013.01); **A61K 33/26** (2013.01); **A61K 45/06** (2013.01); **A61K 47/61** (2017.08); **A61P 7/06** (2018.01); **C08B 31/185** (2013.01); **C08B 37/0009** (2013.01); **Y10S 514/814** (2013.01)

(58) **Field of Classification Search**

CPC .... **A61K 31/295**; **A61K 31/718**; **A61K 33/26**; **A61K 47/61**; **A61P 7/06**; **C08B 31/185**  
USPC ..... 514/502, 54, 58, 59, 777, 814  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

1,129,307 A 2/1915 Marsh  
3,076,798 A 2/1963 Mueller et al.  
3,086,009 A 4/1963 Zuschek et al.  
3,324,109 A 6/1967 Eichel et al.  
3,574,184 A 4/1971 Alsop et al.  
3,591,616 A 7/1971 Baldt  
3,592,889 A 7/1971 Lindvall et al.  
3,639,588 A 2/1972 Alsop et al.  
3,821,192 A 6/1974 Montgomery et al.  
3,908,004 A 9/1975 Kitching  
4,180,567 A 12/1979 Herb  
4,370,476 A 1/1983 Usher et al.  
4,599,405 A 7/1986 Mueller et al.  
4,640,837 A 2/1987 Coleman et al.  
4,788,281 A 11/1988 Tosoni et al.  
5,102,652 A 4/1992 Groman et al.  
5,160,726 A 11/1992 Josephson et al.  
5,624,668 A 4/1997 Lawrence et al.  
5,746,999 A 5/1998 Gries et al.  
5,756,715 A 5/1998 Monte et al.  
5,831,043 A 11/1998 Fleche  
5,866,533 A 2/1999 Beck et al.  
6,599,498 B1 7/2003 Groman et al.  
6,773,924 B2 8/2004 Beck et al.  
6,911,342 B2 6/2005 Helenek et al.  
6,960,571 B2 11/2005 Helenek et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2493806 A 5/2004  
CN 1353194 A 6/2002

(Continued)

OTHER PUBLICATIONS

Product Information of Ferinject for Australia of 2011.  
CARHBT(R2) 2025R-4072R (1965-1971)—Chemical Abstracts Service Registry Handbook Number Section.  
Fong et al., "A Comparison Between Intravenous Iron Polymaltose Complex (Ferrum Hausmann) and Oral Ferrous Fumarate in the Treatment of Iron Deficiency Anaemia in Pregnancy", *Eur. J. Haematology*, vol. 60, pp. 119-124 (1998).

(Continued)

*Primary Examiner* — John Pak

(74) *Attorney, Agent, or Firm* — Polsinelli PC

(57) **ABSTRACT**

Water soluble Iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and medicament for the treatment and prophylaxis of iron deficiency conditions.

**26 Claims, No Drawings**

(56)

## References Cited

## U.S. PATENT DOCUMENTS

7,169,359	B2	1/2007	Helenek et al.
7,612,109	B2	11/2009	Geisser et al.
7,687,273	B2	3/2010	Beck et al.
7,883,897	B2	2/2011	Beck et al.
7,964,568	B2	6/2011	Beck et al.
2003/0232084	A1	12/2003	Groman et al.
2004/0180849	A1	9/2004	Helenek et al.
2006/0116349	A1	6/2006	Helenek et al.
2007/0161600	A1	7/2007	Helenek et al.
2008/0214496	A1	9/2008	Tanner-Baumgartner et al.
2008/0234226	A1	9/2008	Erichsen et al.
2008/0269167	A1	10/2008	Ziegler et al.
2010/0099647	A1	4/2010	Geisser et al.

## FOREIGN PATENT DOCUMENTS

CZ	245379	12/1983
DE	3 443 251 A1	5/1986
DE	696 15 620 T2	4/2002
DE	102 49 552 A1	5/2004
EP	0150085 A2	7/1985
EP	0 427 349 A2	5/1991
EP	0 755 944 A2	1/1997
EP	0 875 249 A1	11/1998
EP	1 719 496 A2	11/2006
FR	1 451 203	1/1966
GB	289 280 A	4/1928
GB	828404 A	2/1960
GB	879441 A	10/1961
GB	928238 A	6/1963
GB	978485 A	12/1964
GB	1 111 929	5/1968
GB	1199951 A	7/1970
GB	1258566 A	12/1971
GB	1377006 A	12/1974
GB	2 129 821 A	5/1984
WO	WO 95/07303 A1	3/1995
WO	WO-95/32978 A1	12/1995
WO	WO-97/11711 A1	4/1997
WO	WO-97/17377 A1	5/1997
WO	WO-00/30657 A1	6/2000
WO	WO-00/66634 A1	11/2000
WO	WO 01/12163 A1	2/2001
WO	WO-02/46241	6/2002
WO	WO-2004/019032 A1	3/2004
WO	WO-2004/037865 A1	5/2004
WO	WO-2004/082693 A1	9/2004
WO	WO-2006/084782 A1	8/2006
WO	WO-2007/023154 A2	3/2007
WO	WO-2007/055804 A2	5/2007
WO	WO-2007/060038 A2	5/2007
WO	WO-2007/081744 A2	7/2007

## OTHER PUBLICATIONS

Rote Liste, product information for Ferrum Hausmann (1996).  
 Römpp encyclopedia chemistry 9 ("Römpp Chemie Lexikon"); 10th edition, vol. 2, Cm-G, p. 213, 1997, catchword "dextrin".  
 Römpp encyclopedia chemistry 9 ("Römpp Chemie Lexikon"); 10th edition, vol. 4, M-Pk, p. 518, 1998, catchword "maltodextrin".  
 German Marketing approval for Ferrum Hausmann (dated 1978).  
 Bolivian Marketing approval for Ferrum Hausmann (dated 1960).  
 Bailie, G., "Breaking New Ground in Intravenous Iron Therapy", *European Haematology*, (2008), pp. 58-60.  
 Ferinject: Product label in Europe.  
 Auerbach, M., et al., "Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety, Hematology", (2010), pp. 338-347.  
 Besemer, A.C., et al., "The Relation between Calcium Sequestering Capacity and Oxidation Degree of Dicarboxy-Starch and Dicarboxy-Inulin", *Stärke-Stärke*, vol. 46, No. 11, (1994), pp. 419-422.  
 De Nooy, A.E.J., et al., "On the Use of Stable Organic Nitroxyl Radicals for the Oxidation of Primary and Secondary Alcohols", *Synthesis*, vol. 10, (1996), pp. 1153-1174.

Besemer, A. C., et al., "Dicarboxy-starch by Sodium Hypochlorite Bromide Oxidation and Its Calcium Binding Properties", *Stärke-Stärke*, vol. 46, No. 3, (1994), pp. 95-101.

Besemer, A.C., et al., "The Hypochlorite Oxidation of Inulin", *Recueil Travaux Chim Pays-Bas*, vol. 113, No. 9, (1994), pp. 398-402.

Besemer, A.C., et al., "The Catalytic Effect of Bromide in the Hypochlorite Oxidation of Linear Dextrins and Inulin", *Stärke-Stärke*, vol. 46, No. 3, (1994), pp. 101-106.

Deary, M.E., et al., "Evidence for Cyclodextrin Dioxiranes", *Carbohydrate Research*, vol. 309, (1998), pp. 17-29.

Kardos, N., et al., "Sonochemistry of Carbohydrate Compounds", *Carbohydrate Research*, vol. 332, (2001), pp. 115-131.

Anelli, P.L., et al., "Fast and Selective Oxidation of Primary Alcohols to Aldehydes or to Carboxylic Acids and of Secondary Alcohols to Ketones Mediated by Oxammonium Salts Under Two-Phase Conditions", *J. of Organic Chemistry*, vol. 52, (1987), pp. 2559-2562.

Dextran Structure, <http://www.dextran.net/dextran-structure.html>.

De Belder, A.N., "Dextran" *Dextran Handbook* (Amersham) (2003), pp. 1-64.

CAS Registry Handbook(R2) 2025R-4072R (1965-1971)—Chemical Abstracts Service Registry Handbook Number Section.

Singh et al., "A Comparison Between Intravenous Iron Polymaltose Complex (Ferrum Hausmann) and Oral Ferrous Fumarate in the Treatment of Iron Deficiency Anaemia in Pregnancy", *Eur. J. Haematology*, vol. 60, pp. 119-124 (1998).

"International Nonproprietary Names for Pharmaceutical Substances (INN)", *World Health Organization*, vol. 22, No. 1 (2008), pp. 41-42, 54.

Bailie, G.R., "Efficacy and Safety of Ferric Carboxymaltose in Correcting Iron-Deficiency Anemia: A Review of Randomized Controlled Trials across Different Indications", *Arzneimittelforschung*, vol. 60, No. 6a, (2010), pp. 386-398.

Burckhardt-Herold, S., et al., "Interactions Between Iron (III)-hydroxide Polymaltose Complex and Commonly Used Drugs", *Arzneimittel-Forschung*, vol. 57, No. 6a, (2007), pp. 360-369.

Burger, K., et al., "A Novel Plynuclear Iron(III) Mixed Ligand Complex for Use in Parenteral Iron Therapy", *Inorganica Chimica Acta*, vol. 80, (1983), pp. 231-235.

Coe, E., et al., "Comparison of Polysaccharide Iron Complexes Used as Iron Supplements", *Journal of Inorganic Biochemistry*, vol. 57, (1995), pp. 287-292.

Devaki, P. B., et al., "Effects of Oral Iron (III) Hydroxide Polymaltose Complex Supplementation of Hemoglobin Increase, Cognitive Function, Affective Behavior and Scholastic Performance of Adolescents with Varying Iron Status", *Arzneimittel-Forschung*, vol. 59, No. 6, (2009), pp. 303-310.

Driss, F., et al., "Effects of Intravenous Polymaltose Iron on Oxidant Stress and Non-Transferrin-Bound Iron in Hemodialysis Patients", *Nephron Clinical Practice*, (2005), vol. 99, pp. 63-67.

European Search Report EP 10 194 332.2, dated Jan. 12, 2011. (See Translation).

Ferrlecit NDA 20-955 Ferrlecit, (1999), pp. 1-10.

Ferrlecit 62,5, Beipackzettel Packungsbelle & Fachinformation, (2011), pp. 1-5. (German).

Funk, F., et al., "Interactions Between Iron (III)-hydroxide Polymaltose Complex and Commonly Used Medications", *Arzneimittel-Forschung (Drug Research)*, vol. 57, No. 6a, (2007), pp. 370-375.

Geetha, K., et al., "Transition-Metal Saccharide Chemistry: Synthesis, Spectroscopy, Electrochemistry and Magnetic Susceptibility Studies of Iron (III) Complexes of Mono- and Disaccharides", *Carbohydrate Research*, vol. 271, (1995), pp. 163-175.

Geisser, P., et al., "Structure/Histotoxicity Relationship of Parenteral Iron Preparations", *Arzneim.-Forsch/Drug Res.*, vol. 42 (ii), No. 12, (1992), pp. 1439-1452.

Geisser, P., "Safety and Efficacy of Iron (III)—hydroxide Polymaltose Complex", *Arzneimittel-Forschung (Drug Research)*, vol. 57, No. 6a, (2007), pp. 439-452.

Kearsley, M. W., et al., "The Determination of the Iron/Chelating Ability of Different Carbohydrates and the Preparation of Ferric/Carbohydrate Complexes", *Acta Alimentaria*, vol. 8, No. 1, (1979), pp. 69-78.

(56)

## References Cited

## OTHER PUBLICATIONS

- Lange, W. E., et al., "Availability of Ionic Iron from Iron Chelates", *J. Pharmac. Sci.*, vol. 51, (1962), pp. 1128-1131.
- Lundqvist, H., et al., "Food Interaction of Oral Uptake of Iron", *Arzneimittel-Forschung (Drug Research)*, vol. 57, No. 6a, (2007), pp. 401-416.
- MacDougall, I. C., "Evolution of Iv Iron Compounds over the Last Century", *Journal of Renal Care*, vol. 35 (s2), (2009), pp. 8-13.
- Mannich, C., et al., "Ueber die kolloide Natur des Eisenzuckers", (1922), p. 158-166.
- Mannich, V.C., et al., "Wissenschaftliche Mitteilungen", *Apotheker-Zeitung*, No. 37, (1913), pp. 329-330. (German) See translation.
- Mannich, V.C., et al., "Wissenschaftliche Mitteilungen", *Apotheker-Zeitung*, No. 37, (1913), pp. 329-330. Machine translation.
- Picaud, J. C., et al., "Supplémentation en fer chez les enfants prématurés traités par érythropoïétine", *Arch Pediatr*, vol. 6, (1999), pp. 657-664.
- Pugh-Clarke, K., et al., "An Evidence-Based Approach to Anaemia Management in Predialysis Chronic Kidney Disease", *Journal of Renal Care*, vol. 35 (s2), (2009), pp. 29-31.
- Qunibi, W. Y., "The Efficacy and Safety of Current Intravenous Iron Preparations for the Management of Iron-Deficiency Anaemia: A Review", *Arzneimittelforschung*, vol. 60, No. 6a, (2010), pp. 399-412.
- Ranfaing, E., "Treatments of the Martial Deficiencies: Preparations Available in France", *Néphrologie & Thérapeutique*, vol. 5, (2006), pp. 5337-5340. (Abstract).
- Rao, C. P., et al., "Fe (III) Complexes of D-glucose and D-Fructose", *BioMetals*, vol. 7, (1994), pp. 25-29.
- Rao, C. P., et al., "Solution Stability of Iron-Saccharide Complexes", *Bioorganic & Medicinal Chemistry Letters*, vol. 2, No. 9, (1992), pp. 997-1002.
- Rao, C. P., et al., "Transition Metal Saccharide Chemistry and Biology: Syntheses, Characterization, Solution Stability and Putative Bio-Relevant Studies of Iron-Saccharide Complexes", *Inorganica Chimica Acta*, vol. 297, (2000), pp. 373-382.
- Tagboto, S., et al., "The Efficacy of a Single Dose of Intravenous Ferric Carboxymaltose (Ferinject®) on Anaemia in a Pre-Dialysis Population of Chronic Kidney Disease Patients", *Journal of Renal Care*, (2009), vol. 35, No. 1, pp. 18-22.
- Tonkovic, M., et al., "Preparation and Properties of Fe(III)-Sugar Complexes", *Inorganica Chimica Acta*, vol. 80, (1983), pp. 251-254.
- Venofor Label, American Regent, Inc. Shirley, NY 11967.
- English translation of CN 1353194 (Jun. 12, 2002), ten pages.
- Dokic et al., "Molecular Characteristics of Maltodextrins and Rheological Behaviour of Diluted and Concentrated Solutions", *Colloids Surfaces A: Physicochem. Eng. Aspects*, vol. 141, (1998), pp. 435-440.
- Thaburet et al., "TEMPO-mediated Oxidation of Maltodextrins and D-glucose: Effect of pH on the Selectivity and Sequestering Ability of the Resulting Polycarboxylates", *Carbohydrate Research*, vol. 330, (2001), pp. 21-29.
- Dokic et al., "Molecular Characteristics of Maltodextrins and Rheological Behaviour of Diluted and Concentrated Solutions", *Colloids Surfaces A: Physicochem. Eng. Aspects*, 141, (1998), pp. 435-440.
- International Search Report for corresponding PCT/EP2003/11596 dated Jan. 23, 2004, 3 pages.
- HCAPLUS Abstract 1960:117732 (1960), one page.
- HCAPLUS Abstract 2003:135397 (2003), one page.
- Ferrlecit Highlights of Prescribing Information (Aug. 2011).
- Marchasin et al., "The Treatment of Iron-Deficiency Anemia with Intravenous Iron Dextran", 1964, *Bl.* 23(3), 354-358.
- U.S. Appl. No. 60/757,119, filed Jan. 6, 2006, Helenek et al.
- Preusser et al., "Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agents", *Clinical and Experimental Pharmacology and Physiology* (2005), 32, 1020-1026.
- Crichton et al., "Iron Therapy with Special Emphasis on Intravenous Administration", UNI-MED, 2005, 2nd edition, cover page, foreword, acknowledgments, preface and contents; and chapters 7, 9, 10 and 11.
- Van Wyck, "Labile Iron: Manifestations and Clinical Implications", (2004) *J. Am. Soc. Nephrology* 15, 5107-5111.
- Dr. Barbara von Eisenhart-Rothe, Reproduction of a speech given at a press conference on Apr. 12, 2005, Subject: "Clinical Development Programme of VIT-45", including Screenshot showing results of google search for "eisenhart rothe vit-45", Screenshot showing document properties of D4, UBS report on Galenica's financial results.
- Manley et al., "Determination of VIT 45 (IND#63,243—American Regent) removal by closed loop in vitro hemodialysis system", *Int J Artif Organs*. Nov. 2006; 29(11):1062-6.
- Excerpt from DER BUND, edition of Apr. 13, 2005.
- Consumer Medicine Information for Promit® "Dextran 1".
- Research Subject Information and Consent Form "Evaluation of the safety, tolerability and pharmacokinetic profiles of single rising doses and increasing administration rates of ABT-870 in ESRO subjects on chronic hemodialysis with iron deficiency anemia", Apr. 2004.
- Spinowitz et al., "The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients", *Kidney International*, vol. 68 (2005), 1801-1807.
- Landry et al., "Pharmacokinetic study of ferumoxytol: A new iron replacement therapy in normal subjects and hemodialysis patients", *American Journal of Nephrology*, vol. 25, No. 4, 2005, pp. 400-410, XP009123870.
- Hunnius Pharmazeutisches Wörterbuch, 8th edition, 1998, p. 710, catchword "Injections".
- Van Zyl-Smit et al., Experience with the Use of an Iron polymaltose (Dextrin) Complex Given by Single Total Dose Infusion to Stable Chronic Haemodialysis Patients; 92 NEPHRON (2002).
- Patent Term Extension Application of U.S. Pat. No. 7,612,109.
- Aronoff, "Safety of Intravenous Iron in Clinical Practice: Implications for Anemia Management Protocols", *Journal of the American Society of Nephrology*, vol. 15, S99-S106 (2004).
- Gupte et al., "Iron Deficiency Anemia: Management and Prevention in Children", *JK Science*, vol. 3(4), 160-165 (2001).
- Venofor® approved by FDA ahead of company expectations for use in USA for treatment of iron deficiency anemia in pre-dialysis patients: <http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=14089>, Jun. 2005.
- Danielson, "Structure, chemistry and pharmacokinetics of intravenous iron agents", *J Am Soc Nephrol* 15, S93-S98 (2004).
- Van Wyck et al., "A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD", *Kidney International*, vol. 68, 2846-2856 (2005).
- Jahn et al., "A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer)(R) a new intravenous iron preparation and its clinical implications", *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 78, 480-491, (2011).
- Assignment of U.S. Appl. No. 11/620,986 dated Mar. 1, 2007 / Mar. 2, 2007.
- Seid et al., "Safety Profile of Iron Carboxymaltose, or Now High Dose Intravenous Iron in Patients", *Blood*, 108(11), 3739 (2006).
- Paschen, *Geburtshilfe Frauenheilkunde*, 9, 604-616 (including English translation) (1949).
- Nissim, Deposition of Iron in the Tests After Administration of an Iron-Dextran Complex, *Lancet*, 268, 701-702 (1955).
- McCurdy et al., "Parenteral Iron Therapy", *New Engl. J. Med.*, 257(24), 1147-1153 (1957).
- Beshara et al., Pharmacokinetics and red cell utilization of <sup>52</sup>Fe/<sup>59</sup>Fe-labelled iron polymaltose in anaemic patients using positron emission tomography, *Brit. J. Haematol.* 120, 853-89 (2003).
- Redacted P-IV Notice of Certification Letter on behalf of Mylan Laboratories Ltd. dated May 7, 2019.
- Fielding, "Intravenous Iron-Dextrin in Iron-Deficiency Anaemia", *British Medical Journal*, Jul. 29, 1961, pp. 270-283.
- Rutenberg et al., "Starch: Chemistry and Technology—Chapter X, Starch Derivatives: Production and Uses", *Academic Press*, 1984, pp. 311-388.

(56)

**References Cited**

## OTHER PUBLICATIONS

- Funk et al., "Physical and Chemical Characterization of Therapeutic Iron Containing Materials: A Study of Several Superparamagnetic Drug Formulations with the  $\beta$ -FeOOH or Ferrihydrite Structure", *Hyperfine Interactions*, Mar. 2001 pp. 73-95.
- Baker et al., "Hydrolysis of Potato and Malt Starches by Malt Amylase Part II: Maltodextrin", *Journal of the Institute of Brewing*, vol. 44, Issue 6, pp. 514-519, Nov.-Dec. 1938.
- Goetsch et al., "Observations on the effect of massive doses of iron given intravenously to patients with hypochromic anemia", *Blood* 1: 129-142, 1946.
- Nagy et al., "Equilibrium and structural studies on metal complexes of carbohydrates and their derivatives", *Journal of Inorganic Biochemistry* 89 (2002) 1-12.
- Gyurscik et al., "Carbohydrates as ligands: coordination equilibria and structure of the metal complexes", *Coordination Chemistry Reviews* 203 (2000) 81-149; p. 107.
- 21 Code of Federal Regulations Sec. 184.1444, Apr. 1, 2015.
- Floor et al., "Oxidation of Maltodextrins and Starch by the System Tungstate—Hydrogen Peroxide", *Starch/Starke* 41 (1989) Nr. 8, S 303-309.
- Pecsok et al., "The Gluconate Complexes. II. The Ferric-Gluconate System", *J. Am. Chem. Soc.*, 1955 77 (6), pp. 1489-1494.
- Floor et al., "Preparation and calcium complexation of oxidized polysaccharides", *Starch-Starke*, 41 (9) : 348-354, 1989.
- Edelman et al., *Journal of Biological Chemistry* 1954-55, 213:843-854.
- Drug Approval Package: Venofer (Iron sucrose) NDA #21135, retrieved Nov. 9, 2015 from [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2000/21135\\_Venofer.cfm](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21135_Venofer.cfm).
- Sucrose is digested to glucose and fructose (Wikipedia), Jul. 15, 2015.
- Glucuronic acid., *A Dictionary of Biology* 2004. Retrieved Jul. 10, 2015 from <http://www.encyclopedia.com/doc/106-glucuronicacid.html>.
- Fel'dman et al., "Methods of Synthesis and Technology of Drug Production. Methods of obtaining D-glucuronic acid from D-glucose. II. Synthesis of glucuronides and their conversion into D-glucuronic acid", *Pharmaceutical Chemistry Journal*, Feb. 1983, vol. 17, Issue 2, pp. 134-140.
- Maltodextrin—Hyet Sweet, <http://www.hyetsweet.com/product/bulkingagents/maltodextrin/> accessed on Jul. 16, 2015.
- P. Lundsgaard-Hansen, "Treatment of Shock with Dextran and Gelatins", *Vox Sang.* 17 161-193 (1969).
- Sellekvold et al., "Procaine Is Effective for Minimizing Postchemic Ventricular fibrillation in Cardiac Surgery", *Anaesthesia*, 1991, vol. 46, pp. 1033-1035.
- Faich et al., "Sodium Ferric Gluconate Complex in Sucrose: Safer Intravenous Iron Therapy Than Iron Dextran", *American Journal of Kidney Diseases*, vol. 33, No. 3 Mar. 1999: pp. 464-470.
- Bailie et al., "Parenteral Iron Use in the Management of Anemia in End-Stage Renal Disease Patients", *American Journal of Kidney Diseases*, vol. 35, No. 1 Jan. 2000: pp. 1-12.
- Steven Fishbane, "Safety in Iron Management American Journal of Kidney Diseases", vol. 41, No. 6, Suppl 5 Jun. 2003: pp. S18-S26. Form 3 detailing the status of corresponding applications filed by the Plaintiff dated May 24, 2005.
- Espacenet Abstract of EP 1554315(a1), A comparison of the said Form 3 with the list of countries where corresponding patent applications has been filed (as obtained from the EPO website). Excerpts from the CAS registry No. 1965-71 (9007-72-1)—Iron Polymaltose.
- Jeanes et al., "Chemical Reactions of the chlorites with carbohydrates" *National Bureau of Standards*, vol. 27, Aug. 1941.
- Ricketts et al. "The Iron Dextran Complex", *Nature*, No. 5007, pp. 237, 239, 1965.
- Kearsley et al., "Handbook of Starch Hydrolysis Products and Their Derivatives", *Maltodextrins*, pp. 65-67 1995 Springer Science+Business Media Dordrecht.
- Redacted P-IV Notice of Certification Letter on behalf of Sandoz Inc. dated Jul. 10, 2019.
- Barbara Jankiewicz et al., The Influence of Molar Mass of Oligosaccharides on Their Ability to Disperse Iron Hydroxide (III), *Acta Poloniae Pharmaceutica-Drug Research*, 1994; pp. 187-189, vol. 51, No. 2.
- Iain C. MacDougall, Strategies for Iron Supplementation: Oral Versus Intravenous, *Kidney International*, 1999, pp. S-61-S-66, vol. 55, Suppl. 69.
- Kanti M. Patel & J.A. Tulloch, Total Dose Imferon (Iron-dextran Complex) Infusion Therapy in Severe Hookworm Anemia, *British Medical Journal*, 1967, pp. 605-607, vol. 2.
- Roger D. Hamstra et al., Intravenous Iron Dextran in Clinical Medicine, *JAMA*, 1980, pp. 1726-1731, vol. 243, No. 17.
- John J. Perkins, Principles and Methods of Sterilization in Health Sciences, 2d Edition, 8th Printing, (1983) pp. 117-118.
- Physician's Desk Reference, 55th Edition (2001) pp. 2879-2881 (INFeD).
- Physician's Desk Reference, 56th Edition (2002) pp. 580-581 (Venofer), 3386-3388 (Ferrlecit).
- INFeD FDA Label, Watson Pharmaceuticals, Inc. (Rev. Jul. 2009).
- Dexferrum FDA Label, American Regent, Inc. (Rev. Aug. 2008).
- Robert T. Morrison & Robert N. Boyd, *Lehrbuch der Organischen Chemie*, 3d Edition, (1983) pp. 1189-1190, 1229-1232.

**AQUEOUS IRON CARBOHYDRATE  
COMPLEXES, THEIR PRODUCTION AND  
MEDICAMENTS CONTAINING THEM**

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 13/556,733, filed Jul. 24, 2012, which is a continuation of U.S. patent application Ser. No. 12/581,212, filed Oct. 19, 2009, which is a division of U.S. application Ser. No. 10/531,895, filed Dec. 14, 2005 and which issued as U.S. Pat. No. 7,612,109 on Nov. 3, 2009, which is a U.S. national stage application under 35 U.S.C. § 371 of PCT/EP2003/011596, filed Oct. 20, 2003, which claims benefit of German Application No. 102 49 552.1, filed Oct. 23, 2002, all of which are incorporated by reference herein in their entirety.

The present invention concerns water-soluble iron carbohydrate complexes which are used for the treatment of iron deficiency anaemia, their preparation, medicaments containing them and their use for the prophylaxis or treatment of iron deficiency anaemia. The medicaments are especially useful for parenteral application.

Iron deficiency anaemia can be treated or prophylactically treated by the application of medicaments containing iron. In this respect the use of iron carbohydrate complexes is known. A water soluble iron (III) hydroxide sucrose complex is a frequently and successfully used preparation (Danielson, Salmonson, Derendorf, Geisser, Drug Res., Vol. 46: 615-621, 1996). It is also known in the art to use, for parenteral application, iron dextran complexes as well as complexes based on pullulans (WO 02/46241), which are difficult to obtain and have to be produced under pressure at high temperatures and involving hydrogenating steps. Other iron carbohydrate complexes are also known for oral application.

The problem to be solved by the present invention is to provide an iron preparation which is especially to be applied parenterally and which can easily be sterilized; the known parenterally applicable preparations on the basis of sucrose and dextran were only stable at temperatures up to 100° C., which made sterilisation difficult. Further, the preparation to be provided by the invention shall have reduced toxicity and shall avoid dangerous anaphylactic shocks which can be induced by dextran. Also, the stability of the complexes of the preparation shall be high in order to enable a high applicable dosage and a high rate of application. Furthermore, the iron preparation is to be producible from easily obtainable starting products and without great effort.

In accordance with the present invention the problem can be solved by providing iron (III) carbohydrate complexes on the basis of the oxidation products of maltodextrins. Therefore, an object of the present invention are water soluble iron carbohydrate complexes which are obtainable from an aqueous solution of an iron (III) salt and an aqueous solution of the oxidation product of one or more maltodextrins, using an aqueous hypochlorite solution at an alkaline pH-value of e.g. 8 to 12 where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40.

A further object of the present invention is a process for producing the iron carbohydrate complexes according to the invention wherein one or more maltodextrins are oxidized in an aqueous solution at an alkaline pH-value of e.g. 8 to 12

using an aqueous hypochlorite solution and reacting the obtained solution with an aqueous solution of an iron (III) salt where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40.

The usable maltodextrins are easily obtainable starting products, and they are commercially available.

In order to prepare the ligands of the complexes of the invention, the maltodextrins are oxidized in an aqueous solution with a hypochlorite solution. Suitable examples are solutions of alkali hypochlorites such as a solution of sodium hypochlorite. Commercially available solutions can be used. The concentration of the hypochlorite solution is, e.g. at least 13% by weight, preferably in the order of 13 to 16% by weight, calculated as active chlorine. Preferably the solutions are used in such an amount that about 80 to 100%, preferably about 90% of one aldehyde group per molecule of maltodextrin is oxidized, in this manner, the reactivity caused by the glucose content of the maltodextrin molecules is lowered to 20% or less, preferably to 10% or less.

The oxidation is carried out in an alkaline solution, e.g. at a pH of 8 to 12, for example 9 to 11. As an example, oxidation can be carried out at temperatures in the order of 15 to 40° C., preferably of 25 to 35° C. The reaction times are, e.g. in the order of 10 minutes to 4 hours, e.g. 1 to 1.5 hours.

By this procedure the degree of depolymerisation of the starting maltodextrins is kept at a minimum. Only theoretically it is assumed that the oxidation occurs mainly at the terminal aldehyde group (acetal or semiacetal group respectively) of the maltodextrin molecules.

It is also possible to catalyse the oxidation reaction of the maltodextrins. The addition of bromide ions is suitable, e.g. in the form of alkali bromides, for example sodium bromide. The added amount of bromide is not critical. The amount is kept as low as possible in order to achieve an end product (Fe-complex) which can easily be purified. Catalytic amounts are sufficient. As stated above, the addition of bromide is possible, however, not necessary.

Further, it is also possible to use other oxidation systems, such as e.g. the known ternary oxidation system hypochlorite/alkali bromide/2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) for the oxidation of the maltodextrins. The process to oxidize maltodextrins catalytically with alkali bromides or with the ternary TEMPO system is described e.g. by Thaburet et al in Carbohydrate Research 330 (2001) 21-29, which method can be used for the present invention.

In order to prepare the complexes of the invention the obtained oxidized maltodextrins are reacted with an iron (III) salt in an aqueous solution. In order to do so, the oxidized maltodextrins can be isolated and redissolved; however, it is also possible to use the obtained aqueous solutions of the oxidized maltodextrins directly for the further reaction with the aqueous iron (III) solutions.

Water soluble salts of inorganic or organic acids, or mixtures thereof, such as halides, e.g. chloride and bromide or sulfates can be used as iron (III) salts. It is preferred to use physiologically acceptable salts. It is especially preferred to use an aqueous solution of iron (III) chloride.

It has been found that the presence of chloride ions favours the formation of the complexes. The chloride ions can be used in the form of water soluble chlorides such as alkali metal chlorides, e.g. sodium chloride, potassium chlo-

ride or ammonium chloride. As stated, the iron (III) is preferably used in the form of the chloride.

For instance, the aqueous solution of the oxidized maltodextrin can be mixed with an aqueous solution of the iron (III) salt in order to carry out the reaction. Here, it is preferred to proceed in a manner so that during and immediately after mixing of the oxidized maltodextrin and the iron (III) salt, the pH is strongly acid or so low that no hydrolysis of the iron (III) salt occurs, e.g. 2 or less, in order to avoid an undesired precipitation of iron hydroxides. In general, it is not necessary to add an acid, if iron (III) chloride is used, since aqueous solutions of iron (III) chloride can be sufficiently acid. Only after mixing, the pH is raised to values of e.g. in the order of at least 5, for example up to 11, 12, 13 or 14. The pH is preferably raised slowly or gradually which, for example, can be achieved by first adding a weak base, for example, up to a pH of about 3, and then neutralizing further using a stronger base. Examples of weak bases are alkali—or alkaline earth—carbonates, bicarbonates, such as sodium and potassium carbonate or bicarbonate, or ammonia. Examples of strong bases are alkali—or alkaline earth—hydroxides such as sodium, potassium, calcium or magnesium hydroxide.

The reaction can be improved by heating. For example, temperatures in the order of 15° C. up to boiling point can be used. It is preferred to raise the temperature gradually. Thus, for example, it is possible to heat to about 15 to 70° C. and then raise the temperature gradually up to boiling point.

The reaction times are, for example, in the order of 15 minutes up to several hours, e.g. 20 minutes to 4 hours, such as 25 to 70 minutes, e.g. 30 to 60 minutes.

The reaction can be carried out in a weakly acid range, for example, at a pH in the order of 5 to 6. However, it has been found, that it is useful, but not necessary, to raise the pH during the formation of the complexes to higher values of up to 11, 12, 13 or 14. In order to complete the reaction, the pH can be lowered then by addition of an acid, for example, to the order of 5 to 6. It is possible to use inorganic or organic acids or mixture thereof, especially hydrogen halide acids such as hydrogen chloride or aqueous hydrochloric acid respectively.

As stated above, the formation of the complexes is usually improved by heating. Thus, at the preferred embodiment of the invention, wherein the pH is raised during the reaction to ranges of at least 5 and above up to 11 or 14. It is, for instance, possible to work at first at lower temperatures in the order of 15 to 70° C., such as 40 to 60° C., e.g. about 50° C., whereafter the pH is reduced to values in the order of at least 5 and the temperature is gradually raised over 50° C. up to boiling point.

The reaction times are in the order of 15 minutes up to several hours and they can vary depending on the reaction temperature. If the process is carried out with an intermediate pH of more than 5, it is, for example, possible to work 15 to 70 minutes, e.g. 30 to 60 minutes, at the enhanced pH, for example at temperatures of up to 70° C., whereafter the pH is lowered to a range in the order of at least 5 and the reaction is carried out for a further 15 to 70 minutes, e.g. 30 to 60 minutes, at temperatures e.g. up to 70° C., and optionally a further 15 to 70 minutes, e.g. 30 to 60 minutes, at higher temperatures up to boiling point.

After the reaction the obtained solution can be cooled to e.g. room temperature and can optionally be diluted and optionally be filtered. After cooling, the pH can be adjusted to the neutral point or a little below, for example, to values of 5 to 7, by the addition of an acid or base. It is possible to

use e.g. the acids and bases which have been mentioned for carrying out the reaction. The solutions obtained are purified and can directly be used for the production of medicaments. However, it is also possible to isolate the iron (III) complexes from the solution e.g. by precipitation with an alcohol such as an alkanol, for example, ethanol. Isolation can also be effected by spray-drying. Purification can take place in the usual way, especially in order to remove salts. This can, for example, be carried out by reverse osmosis. It is, for example, possible to carry out the reverse osmosis before spray-drying or before a direct application in medicaments.

The iron content of the obtained iron (III) carbohydrate complexes is, for example, 10 to 40% weight/weight, especially, 20 to 35% weight/weight. They can easily be dissolved in water. It is possible to prepare neutral aqueous solutions which, e.g. have an iron content of 1% weight/vol. to 20% weight/vol. Such solutions can be sterilised thermally. The weight average molecular weight mw of the obtained complexes, is, for example, 80 kDa to 400 kDa, preferably 80 kDa to 350 kDa, especially preferred up to 300 kDa (measured by gel permeation chromatography, e.g. as described by Geisser et al, in *Arzneim, Forsch/Drug Res.* 42(11), 12, 1439-1452 (1992), paragraph 2.2.5),

As stated above, it is possible to provide aqueous solutions from the complexes of the invention. These solutions are especially useful for parenteral application. However, it is also possible to apply them orally or topically. Contrary to the known parenterally applicable iron preparations they can be sterilized at high temperatures, e.g. at 121° C. and above, at short contact times of, e.g. 15 minutes, by acquiring  $F_0 \geq 15$ . The contact times are correspondingly shorter at higher temperatures. Preparations hitherto known had to be sterilely filtrated and mixed with preservatives, such as benzyl alcohol or phenol. Such additives are not necessary in the invention. Hence, it is possible to fill the solutions of the complexes, for example, into ampoules. It is, for example, possible, to fill solutions having a content of 1 to 20% by weight, e.g. 5% by weight, into vessels such as ampoules or phials of e.g. 2 to 100 ml, e.g., up to 50 ml. The preparation of the parenterally applicable solutions can be carried out as known in the art, optionally using additives which are normally used for parenteral solutions. The solutions can be formulated in such a way that they can be administered by injection or in the form of an infusion, e.g., in brine solution. For the oral or topical application it is possible to formulate preparations with usual excipients and additives.

Thus, a further object of the invention are aqueous medicaments which are especially useful for the parenteral, intravenous but also intramuscular application as well as for the oral or topical application; they are especially useful for the treatment of iron deficiency anaemia. A further object of the invention is also the use of the iron (III) carbohydrate complexes according to the invention for the treatment and prophylaxis of iron deficiency anaemia or the production of medicaments especially for the parenteral treatment iron deficiency anaemia. The medicaments can be used in human and veterinary medicine.

The advantages which are achieved with the iron (III) carbohydrate complexes of the invention are the above-mentioned high sterilisation temperatures as well as the low toxicity and the reduced danger of anaphylactic shock. The toxicity of the complexes according to the invention is very low. The LD<sub>50</sub> lies at over 2000 mg Fe/kg, compared to the LD<sub>50</sub> of the known pullulan complexes, which lies at 1400 mg Fe/kg. In view of the high stability of the complexes of the invention, it is possible to enhance the rates of applica-

## 5

tion as well as the dosages. Thus, it is possible to apply the medicaments of the invention parenterally in the form of a single dose. Such a single dose is, for example, 500 to 1000 mg iron; it can be applied, for example, during the course of one hour. A further advantage lies in the high degree of availability of the maltodextrins used as starting products, which are, e.g., commercially available additives in the food processing industry.

In the present description, as well as in the following examples, the dextrose equivalents are measured gravimetrically. In order to do so, the maltodextrins are reacted in a boiling aqueous solution with Fehling's solution. The reaction is carried out quantitatively, i.e. until the Fehling's solution is no longer discoloured. The precipitated copper (I) oxide is dried at 105° C. until a constant weight is achieved and measured gravimetrically. The glucose content (dextrose equivalent) is calculated from the obtained results as % weight/weight of the maltodextrin dry substance. It is, for example, possible to use the following solutions: 25 ml Fehling's solution I, mixed with 25 ml Fehling's solution II; 10 ml aqueous maltodextrin solution (10% mol/vol) (Fehling's solution I: 34.6 g copper (II) sulfate dissolved in 500 ml water; Fehling's solution II: 173 g potassium sodium tartrate and 50 g sodium hydroxide dissolved in 400 ml water),

## EXAMPLE 1

100 g maltodextrin (9.6 dextrose equivalent measured gravimetrically) are dissolved by stirring in 300 ml water at 25° C. and oxidized by addition of 30 g sodium hypochlorite solution (13 to 16 weight percent active chlorine) at pH 10.

At first, the oxidized maltodextrin solution and then 554 g sodium carbonate solution (17.3% weight/weight) are added at room temperature to 352 g of a stirred iron (III) chloride solution (12% weight by weight Fe).

Then, the pH is adjusted to 11 by addition of sodium hydroxide and the solution is heated to 50° C. and kept at 50° C. for 30 minutes. Then, acidification to a pH of 5 to 6 is effected by addition of hydrochloric acid, the solution is kept at 50° C. for a further 30 minutes and then heated to 97-98° C. and the temperature is kept for 30 minutes at this range. After cooling the solution to room temperature, the pH is adjusted to 6-7 by the addition of sodium hydroxide.

The solution is then filtered through a sterilisation filter and then examined for sediments. Thereafter, the complex is isolated by precipitation with ethanol in a range of 1:0.85 and then dried in vacuum at 50° C.

The yield is 125 g (corresponding to 87% of the theoretical value) of a brown amorphous powder having an iron content of 29.3% weight/weight (measured complexometrically).

Molecular weight mw 271 kDa.

## EXAMPLE 2

200 g maltodextrin (9.6 dextrose equivalent measured gravimetrically) are dissolved by stirring in 300 ml water at 25° C. and oxidized by addition of 30 g sodium hypochlorite solution (13 to 16 weight percent active chlorine) at pH 10.

At first the oxidized maltodextrin solution and then 554 g sodium carbonate solution (17.3% weight/weight) are added at room temperature to 352 g of a stirred iron (III) chloride solution (12% weight by weight Fe).

Then the pH is adjusted to 11 by addition of sodium hydroxide and the solution is heated to 50° C. and kept for 30 minutes at 50° C. Then, acidification to a pH of 5 to 6 is

## 6

effected by addition of hydrochloric acid, the solution is kept at 50° C. for a further 30 minutes and then heated to 97-98° C. and the temperature is kept for 30 minutes at this range. After cooling the solution to room temperature the pH is adjusted to 6-7 by the addition of sodium hydroxide.

The solution is then filtered through a sterilisation filter and then examined for sediments. Thereafter, the complex is isolated by precipitation with ethanol in a range of 1:0.85 and then dried in vacuum at 50° C.

The yield is 123 g (corresponding to 65% of the theoretical value) of a brown amorphous powder having an iron content of 22.5% weight/weight (measured complexometrically).

Molecular weight mw 141 kDa.

## EXAMPLE 3

100 g maltodextrin (9.6 dextrose equivalent measured gravimetrically) are dissolved by stirring in 300 ml water at 25° C. and oxidized by addition of 30 g sodium hypochlorite solution (13 to 16 weight percent active chlorine) and 0.7 g sodium bromide at pH 10.

At first the oxidized maltodextrin solution and then 554 g sodium carbonate solution (17.3% weight/weight) are added at room temperature to 352 g of a stirred iron (III) chloride solution (12% weight by weight Fe).

Then the pH is adjusted to 6.5 by addition of sodium hydroxide and the solution is heated to 50° C. and kept for 60 minutes at 50° C. Then, acidification to a pH of 5 to 6 is effected by addition of hydrochloric acid, the solution is kept at 50° C. for a further 30 minutes and then heated to 97-98° C. and the temperature is kept for 30 minutes at this range. After cooling the solution to room temperature the pH is adjusted to 6-7 by the addition of sodium hydroxide.

The solution is then filtered through a sterilisation filter and then examined for sediments. Thereafter, the complex is isolated by precipitation with ethanol in a range of 1:0.85 and then dried in vacuum at 50° C.

The yield is 139 g (corresponding to 88% of the theoretical value) of a brown amorphous powder having an iron content of 26.8% weight/weight (measured complexometrically).

Molecular weight mw 140 kDa.

## EXAMPLE 4

A mixture of 45 g maltodextrin (6.6 dextrose equivalent measured gravimetrically) and 45 g maltodextrin (14.0 dextrose equivalent measured gravimetrically) is dissolved by stirring in 300 ml water at 25° C. and oxidized by addition of 25 g sodium hypochlorite solution (13 to 16 weight percent active chlorine) and 0.6 g sodium bromide at pH 10.

At first the oxidized maltodextrin solution and then 554 g sodium carbonate solution (17.3% weight/weight) are added at room temperature to 352 g of a stirred iron (III) chloride solution (12% weight by weight Fe).

Then the pH is adjusted to 11 by addition of sodium hydroxide and the solution is heated to 50° C. and kept for 30 minutes at 50° C. Then, acidification to a pH of 5 to 6 is effected by addition of hydrochloric acid, the solution is kept at 50° C. for a further 30 minutes and then heated to 97-98° C. and the temperature is kept for 30 minutes at this range. After cooling the solution to room temperature the pH is adjusted to 6-7 by the addition of sodium hydroxide.

The solution is then filtered through a sterilisation filter and then examined for sediments. Thereafter, the complex is

## 7

isolated by precipitation with ethanol in a range of 1:0.85 and then dried in vacuum at 50° C.

The yield is 143 g (corresponding to 90% of the theoretical value) of a brown amorphous powder having an iron content of 26.5% weight/weight (measured complexometrically).

Molecular weight mw 189 kDa.

## EXAMPLE 5

90 g maltodextrin (14.0 dextrose equivalent measured gravimetrically) are dissolved by stirring in 300 ml water at 25° C. and oxidized by addition of 35 g sodium hypochlorite solution (13 to 16 weight percent active chlorine) and 0.6 g sodium bromide at pH 10.

At first, the oxidized maltodextrin solution and then 554 g sodium carbonate solution (17.3% weight/weight) are added at room temperature to 352 g of a stirred iron (III) chloride solution (12% weight by weight Fe).

Then the pH is adjusted to 11 by addition of sodium hydroxide and the solution is heated to 50° C. and kept for 30 minutes at 50° C. Then, acidification to a pH of 5 to 6 is effected by addition of hydrochloric acid, the solution is kept at 50° C. for a further 30 minutes and then heated to 97-98° C. and the temperature is kept for 30 minutes at this range. After cooling the solution to room temperature the pH is adjusted to 6-7 by the addition of sodium hydroxide.

The solution is then filtered through a sterilisation filter and then examined for sediments. Thereafter, the complex is isolated by precipitation with ethanol in a range of 1:0.85 and then dried in vacuum at 50° C.

The yield is 131 g (corresponding to 93% of the theoretical value) of a brown amorphous powder having an iron content of 29.9% weight/weight (measured complexometrically).

Molecular weight mw 118 kDa.

## EXAMPLE 6

A mixture of 45 g maltodextrin (5.4 dextrose equivalent measured gravimetrically) and 45 g maltodextrin (18.1 dextrose equivalent measured gravimetrically) is dissolved by stirring in 300 ml water at 25° C. and oxidized by addition of 31 g sodium hypochlorite solution (13 to 16 weight percent active chlorine) and 0.7 g sodium bromide at pH 10.

At first the Oxidized maltodextrin solution and then 554 g sodium carbonate solution (17.3% weight/weight) are added at room temperature to 352 g of a stirred iron (III) chloride solution (12% weight by weight Fe).

Then the pH is adjusted to 11 by addition of sodium hydroxide and the solution is heated to 50° C. and kept for 30 minutes at 50° C. Then, acidification to a pH of 5 to 6 is effected by addition of hydrochloric acid, the solution is kept at 50° C. for a further 30 minutes and then heated to 97-98° C. and the temperature is kept for 30 minutes at this range. After cooling the solution to room temperature the pH is adjusted to 6-7 by the addition of sodium hydroxide.

The solution is then filtered through a sterilisation filter and then examined for sediments. Thereafter, the complex is isolated by precipitation with ethanol in a range of 1:0.85 and then dried in vacuum at 50° C.

The yield is 134 g (corresponding to 88% of the theoretical value) of a brown amorphous powder having an iron content of 27.9% weight/weight (measured complexometrically).

Molecular weight mw 178 kDa.

## 8

## EXAMPLE 7

100 g maltodextrin (9.6 dextrose equivalent measured gravimetrically) are dissolved by stirring in 300 ml water at 25° C. and oxidized by addition of 29 g sodium hypochlorite solution (13 to 16 weight percent active chlorine) and 0.7 g sodium bromide at pH 10.

At first the oxidized maltodextrin solution and then 554 g sodium carbonate solution (17.3% weight/weight) are added at room temperature to 352 g of a stirred iron (III) chloride solution (12% weight by weight Fe).

Then the pH is adjusted to 11 by addition of sodium hydroxide and the solution is heated to 50° C. and kept for 30 minutes at 50° C. Then, acidification to a pH of 5 to 6 is effected by addition of hydrochloric acid, the solution is kept at 50° C. for a further 70 minutes. After cooling the solution to room temperature the pH is adjusted to 6-7 by the addition of sodium hydroxide.

The solution is then filtered through a sterilisation filter and then examined for sediments. Thereafter, the complex is isolated by precipitation with ethanol in a range of 1:0.85 and then dried in vacuum at 50° C.

The yield is 155 g (corresponding to 90% of the theoretical value) of a brown amorphous powder having an iron content of 24.5% weight/weight (measured complexometrically).

Molecular weight mw 137 kDa.

## EXAMPLE 8

126 g maltodextrin (6.6 dextrose equivalent measured gravimetrically) are dissolved by stirring in 300 ml water at 25° C. and oxidized by addition of 24 g sodium hypochlorite solution (13 to 16 weight percent active chlorine) and 0.7 g sodium bromide at pH 10.

At first the oxidized maltodextrin solution and then 554 g sodium carbonate solution (17.3% weight/weight) are added at room temperature to 352 g of a stirred iron (III) chloride solution (12% weight by weight Fe).

Then the pH is adjusted to 11 by addition of sodium hydroxide and the solution is heated to 50° C. and kept for 30 minutes at 50° C. Then, acidification to a pH of 5 to 6 is effected by addition of hydrochloric acid, the solution is kept at 50° C. for a further 70 minutes. After cooling the solution to room temperature the pH is adjusted to 6-7 by the addition of sodium hydroxide.

The solution is then filtered through a sterilisation filter and then examined for sediments. Thereafter, the complex is isolated by precipitation with ethanol in a range of 1:0.85 and then dried in vacuum at 50° C.,

The yield is 171 g (corresponding to 86% of the theoretical value) of a brown amorphous powder having an iron content of 21.35% Weight/weight (measured complexometrically).

Molecular weight mw 170 kDa.

## Comparative Test

In the following the characteristics of the iron carbohydrate complexes are compared with a commercially available iron sucrose complex. It can be seen that the iron content can be enhanced, the thermal treatment can be carried out at higher temperatures and the toxicity (LD<sub>50</sub>) can be lowered in accordance with the invention.



	According to the invention	Iron hydroxide/sucrose complex
Fe content [%]	5.0	2.0
pH	5-7	10.5-11.0
mw [kDa] <sup>1)</sup>	80-350	34-54
Thermal treatment	121° C./15'	100° C./35'
LD <sub>50</sub> l.v., w.m. [mg Fe/kg body weight]	>2000	>200

The invention claimed is:

**1.** An iron (III) carboxymaltodextrin complex wherein said iron (III) carboxymaltodextrin complex comprises polynuclear iron (III)-hydroxide 4(R)-(poly-(1→4)-O-α-D-glucopyranosyl)-oxy-2(R),3(S),5(R),6-tetrahydroxy-hexanoate and has a weight average molecular weight in the range of from 80 kDa to 400 kDa, and wherein said 4(R)-(poly-(1→4)-O-α-D-glucopyranosyl)-oxy-2(R),3(S),5(R),6-tetrahydroxy-hexanoate is derived from the oxidation of maltodextrin, wherein when one maltodextrin is applied its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrins contained in the mixture lies between 2 and 40.

**2.** The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight in the range of from 80 kDa to 350 kDa.

**3.** The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight in the range of from 80 kDa to 300 kDa.

**4.** The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight in the range of from 118 kDa to 271 kDa.

**5.** The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 271,000 Da.

**6.** The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 141,000 Da.

**7.** The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 140,000 Da.

**8.** The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 189,000 Da.

**9.** The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 118,000 Da.

**10.** The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 178,000 Da.

**11.** The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 137,000 Da.

**12.** The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 170,000 Da.

**13.** A medicament comprising the iron (III) carboxymaltodextrin complex of claim 1 and a pharmaceutically acceptable carrier, excipient, or additive.

**14.** The medicament of claim 13, wherein said medicament is an aqueous solution.

**15.** The medicament of claim 14, wherein said aqueous solution is a brine solution.

**16.** The medicament of claim 14, wherein said iron (III) carboxymaltodextrin complex is present in said aqueous solution in an amount of from 1% to 20% by weight, based on the total weight of the aqueous solution.

**17.** The medicament of claim 14, wherein said iron (III) carboxymaltodextrin complex is present in said aqueous solution in an amount of 5% by weight, based on the total weight of the aqueous solution.

**18.** A method for treating an iron deficiency condition comprising the step of administering to a subject in need thereof a pharmaceutically effective amount of the medicament of claim 13.

**19.** The method of claim 18, wherein said iron deficiency condition is iron deficiency anaemia.

**20.** The method of claim 18, wherein said medicament is administered parenterally or orally.

**21.** The method of claim 18, wherein said medicament is administered intravenously or intramuscularly.

**22.** The method of claim 18, wherein said medicament is administered via injection.

**23.** The method of claim 18, wherein said medicament is administered via infusion.

**24.** The method of claim 18, wherein said medicament is administered in the form of a single dose.

**25.** The method of claim 24, wherein said single dose comprises from 500 to 1000 mg of iron.

**26.** The method of claim 25, wherein said single dose is applied during the course of one hour.

\* \* \* \* \*